ID

16455

Description

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00283608

Lien

https://clinicaltrials.gov/show/NCT00283608

Mots-clés

  1. 17/07/2016 17/07/2016 -
Téléchargé le

17 juillet 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT00283608

Eligibility Breast Cancer NCT00283608

Criteria
Description

Criteria

diagnosis of breast cancer
Description

Breast cancer

Type de données

boolean

Alias
UMLS CUI [1]
C0678222
stage i, ii, or iii disease
Description

Tumor stage

Type de données

boolean

Alias
UMLS CUI [1]
C1300072
resected disease
Description

Resection

Type de données

boolean

Alias
UMLS CUI [1]
C0728940
planning to undergo treatment with anastrozole at the clinically approved dose of 1 mg/day or mayo clinic cancer center rochester patient who will be enrolled on or has been enrolled on can-ncic-ma27 and has not started taking the study medication (anastrozole or exemestane)
Description

Planned treatment with anastrozole

Type de données

boolean

Alias
UMLS CUI [1,1]
C3641097
UMLS CUI [1,2]
C0290883
hormone receptor status:
Description

hormone receptor status

Type de données

boolean

Alias
UMLS CUI [1]
C0019929
estrogen receptor-positive and/or progesterone receptor-positive primary tumor
Description

estrogen receptor-positive and/or progesterone receptor-positive primary tumor

Type de données

boolean

Alias
UMLS CUI [1]
C2919271
UMLS CUI [2]
C2919590
patient characteristics:
Description

Patient characteristics

Type de données

boolean

Alias
UMLS CUI [1]
C0815172
female
Description

Gender

Type de données

boolean

Alias
UMLS CUI [1]
C0079399
postmenopausal
Description

Menopausal status

Type de données

boolean

Alias
UMLS CUI [1]
C0025320
able to complete questionnaires alone or with assistance
Description

Questionnaire

Type de données

boolean

Alias
UMLS CUI [1]
C0034394
prior concurrent therapy:
Description

Prior concurrent therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0009429
more than 6 months since prior endocrine therapy, except tamoxifen
Description

prior endocrine therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0279025
no other prior aromatase inhibitors (e.g., letrozole or exemestane)
Description

Aromatase inhibitors

Type de données

boolean

Alias
UMLS CUI [1]
C0593802
no prior ovarian function suppression with surgery or radiotherapy, ovarian ablation, or luteinizing hormone-releasing hormone analogues (e.g., goserelin) as treatment for cancer
Description

Ovarian suppression

Type de données

boolean

Alias
UMLS CUI [1]
C0677922

Similar models

Eligibility Breast Cancer NCT00283608

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Breast cancer
Item
diagnosis of breast cancer
boolean
C0678222 (UMLS CUI [1])
Tumor stage
Item
stage i, ii, or iii disease
boolean
C1300072 (UMLS CUI [1])
Resection
Item
resected disease
boolean
C0728940 (UMLS CUI [1])
Planned treatment with anastrozole
Item
planning to undergo treatment with anastrozole at the clinically approved dose of 1 mg/day or mayo clinic cancer center rochester patient who will be enrolled on or has been enrolled on can-ncic-ma27 and has not started taking the study medication (anastrozole or exemestane)
boolean
C3641097 (UMLS CUI [1,1])
C0290883 (UMLS CUI [1,2])
hormone receptor status
Item
hormone receptor status:
boolean
C0019929 (UMLS CUI [1])
estrogen receptor-positive and/or progesterone receptor-positive primary tumor
Item
estrogen receptor-positive and/or progesterone receptor-positive primary tumor
boolean
C2919271 (UMLS CUI [1])
C2919590 (UMLS CUI [2])
Patient characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Gender
Item
female
boolean
C0079399 (UMLS CUI [1])
Menopausal status
Item
postmenopausal
boolean
C0025320 (UMLS CUI [1])
Questionnaire
Item
able to complete questionnaires alone or with assistance
boolean
C0034394 (UMLS CUI [1])
Prior concurrent therapy
Item
prior concurrent therapy:
boolean
C0009429 (UMLS CUI [1])
prior endocrine therapy
Item
more than 6 months since prior endocrine therapy, except tamoxifen
boolean
C0279025 (UMLS CUI [1])
Aromatase inhibitors
Item
no other prior aromatase inhibitors (e.g., letrozole or exemestane)
boolean
C0593802 (UMLS CUI [1])
Ovarian suppression
Item
no prior ovarian function suppression with surgery or radiotherapy, ovarian ablation, or luteinizing hormone-releasing hormone analogues (e.g., goserelin) as treatment for cancer
boolean
C0677922 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial